Gain insight into the industry's current progress in addressing sustainability challenges and the effects of prioritizing environmental initiatives from a survey on global biopharmaceutical sustainability that collected responses from 800 pharma and biopharma executives across 18 countries.
Scope 3 emissions are particularly complex, as they encompass emissions generated throughout the entire biopharma value chain. Given the numerous stakeholders involved throughout a product's lifecycle and the limited direct control companies have, how can organizations effectively measure and manage this critical aspect of sustainability?
To achieve global sustainability goals, the biopharma industry must minimize the environmental impact of drugs and their development processes from start to finish. Explore some of the biggest obstacles companies are encountering and what is being done to move the industry closer to significant sustainability progress and environmental wins.
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies that are setting the standard? Discover how biopharma companies are prioritizing sustainability as well as the progress that has already been made.
Transformative healthcare should not compromise the health of our planet. What actions are biopharma leaders worldwide taking to enhance sustainability? What challenges are they encountering? And how can the broader industry learn from the companies paving the way? Examine key findings from a biopharma sustainability review.
800 biopharma professionals from 18 different countries were surveyed to assess the progress the industry has made relating to sustainability. Watch to explore the findings that were uncovered from this year's biopharma sustainability review.
This website uses cookies to ensure you get the best experience on our website. Learn more
